Italian Company Seeks Foothold In U.S. Science

With a neuroscience institute in Washington and an emphasis on basic research, FIDIA aims to bolster respect worldwide WASHINGTON - Long after the vinyl and paper folders from a typical scientific conference have been tossed in the trash, a genuine imported leather portfolio with bright red decorative stitching and the inscription: "FIDIA-Georgetown Institute for the Neurosciences, November 3, 1985" is likely to remain on the shelves of many scientists. It's just too nice to throw away. That

Written byJules Asher
| 9 min read

Register for free to listen to this article
Listen with Speechify
0:00
9:00
Share


With a neuroscience institute in Washington and an emphasis on basic research, FIDIA aims to bolster respect worldwide
WASHINGTON - Long after the vinyl and paper folders from a typical scientific conference have been tossed in the trash, a genuine imported leather portfolio with bright red decorative stitching and the inscription: "FIDIA-Georgetown Institute for the Neurosciences, November 3, 1985" is likely to remain on the shelves of many scientists. It's just too nice to throw away.

That kind of staying power was precisely what FIDIA, an Italian drug company, hoped to achieve when it hired a top designer to help it celebrate its inaugural symposium here four years ago. The portfolio, designed to be a lasting souvenir, also illustrates the ingratiating style with which the expansionist firm has successfully courted an initially wary American neuroscience community. That style has featured an elegant banquet in the imposing grand hall of Washington's ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies